key: cord-0779892-vdum2m4m
authors: Nafakhi, Ahmed; Rabeea, Ihsan S.; Al‐Darraji, Rasha; Nafakhi, Hussein; Mechi, Ahmed; Al‐Khalidi, Alhan; alareedh, Mohammed
title: Association of ABO blood group with in‐hospital adverse outcome and long term persistent symptoms of COVID‐19 infection: A single‐center longitudinal observational study
date: 2022-05-23
journal: Health Sci Rep
DOI: 10.1002/hsr2.656
sha: af31da14d6a5f416b92c0d123bc6f060fb6b9e60
doc_id: 779892
cord_uid: vdum2m4m

BACKGROUND AND AIMS: There are gaps in knowledge regarding the association between the ABO blood group and coronavirus disease 2019 (COVID‐19) immediate and long‐term outcomes. We aimed to investigate the association of ABO blood group with COVID‐19 in‐hospital adverse outcomes and to determine whether ABO blood group is associated with post‐COVID‐19 persistent symptoms. METHODS: This was a single‐center longitudinal observational study that included patients who presented with symptoms suggestive of COVID‐19 infection and a positive test for COVID‐19 and were able to attend the out‐patient clinic after 6 months following acute COVID‐19. The main outcomes were intensive care unit admission, the requirement for respiratory support, in‐hospital death, and persistent symptoms. χ (2) test and regression analysis were used to analyze the collected data. RESULTS: A total of 169 patients were enrolled for the assessment of in‐hospital adverse outcomes of whom 86 patients were included for the assessment of persistent symptoms after the exclusion of deceased patients or patients not attended the out‐patient clinic. Patients with blood group B had higher prevalence of in‐hospital death compared to blood group O (39% vs. 13%, p = 0.01) and this persisted after adjusting for sex (odds ratio, OR [confidence interval, CI] = 1.4 [1.1–2.1], p = 0.04), while patients with blood group AB had higher prevalence of requiring respiratory support than blood group O (54% vs. 10%, p = 0.02) and this persisted after adjusting for age (OR [CI] = 1.5 [1.1–2.3], p = 0.02). Concerning the association of ABO blood group and long‐term symptoms, blood group AB showed a higher prevalence of palpitation (p < 0.001) and dizziness (p = 0.02) than other blood groups. CONCLUSIONS: Blood groups AB and B are significantly associated with respiratory support use and in‐hospital death, respectively, compared to blood group O. Blood group AB is significantly associated with persistent palpitation and dizziness compared to other blood groups.

A rapidly spread coronavirus disease 2019 caused by an emerging coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is associated with protean clinical manifestations, ranging from asymptomatic/mild symptoms to respiratory failure and even death. 1,2 Persistent symptoms were observed following the acute phase of COVID-19 infection causing significant disability in the long term. 3, 4 Until April 14, 2022, there have been 500,186,525 confirmed cases of COVID-19, including 6, 190 ,349 deaths worldwide according to World Health Organization (WHO) data. The basic reproduction number of the new SARS-CoV-2 is estimated to be in the range between 1.4 and 3.9, and the infectivity of the virus is higher than other viruses, such as seasonal influenza and the Middle East respiratory syndrome. 5 According to WHO reports, there is no effective treatment for COVID-19 infection and the best approach against the coronavirus is prevention programs such as avoiding close contact with other people and wearing a mask. 6 Hence, determining the clinical or biological risk factors associated with COVID-19 mortality and morbidity is of paramount importance for health decisions and implications of preventive strategies. 5 In the literature, the ABO blood group was found to be significantly associated with cardiovascular disease, cancers, and several viral infections, including hepatitis B virus, SARS, influenza, Rotavirus, and Ebola virus. [7] [8] [9] [10] Multiple hypotheses have been suggested to account for the association between the ABO blood group and viral infections and these include the presence of anti-A antibodies which could prevent the interaction between viral particles and receptors on the cell surface as epithelial cells express ABO blood type antigens, genetic variations in the ABO gene, plasma levels of von Willebrand factor and factor VIII, and variation in the expression of angiotensinconverting enzyme (ACE). 2, [9] [10] [11] [12] Nonetheless, the exact underlying mechanism of this association is still not fully understood.

Early during the COVID-19 pandemic, it has proposed that SARS-CoV-2 receptor-binding domain, which is responsible for the initial host cell, preferentially binds to the blood group A expressed on respiratory epithelial cells. This preferential binding may influence COVID-19 infection acquisition and contribute to disease progression. 2 At present, there are conflicting and nonconclusive results regarding the association of the ABO blood group with COVID-19 morbidity and mortality. Also, the potential links between the ABO blood group and postacute COVID-19 persistent symptoms have been far less studied in the literature. While several observational and meta-analysis studies showed a significant association between ABO blood group and COVID-19 infection susceptibility and severity, 6, 8, 13, 14 other studies showed no association between ABO blood group and COVID-19-related morbidity and mortality. 7, 15, 16 In an attempt to address the gaps in knowledge regarding the potential link between ABO blood group and COVID-19 immediate and long-term outcomes, we aimed to investigate the association of ABO blood group with in-hospital adverse outcomes related to COVID-19 infection and to determine whether ABO blood group is associated with post-COVID-19 persistent symptoms.

This is a single-center, observational and longitudinal study that Regarding the assessment of long-term persistent symptoms, patients who survived acute infection were invited to attend the outpatient clinic after 6 months following COVID-19 illness diagnosis.

Data on long-term symptoms were obtained by asking the patients to mark out symptoms from a predesigned questionnaire, including shortness of breath interfering with routine daily activities, easy fatigue, cough, chest pain, palpitation, joint pain, dizziness, headache, smell loss, and taste loss. If there was a new symptom not mentioned in the questionnaire list, patients were asked to report it. Verbal consent was obtained from the patients or their relatives. Approval of 

Sample size calculation was not performed a priori, and the sample size was equal to the number of patients who met the inclusion criteria during the study period. Statistical analyses were achieved using Statistical Package for Social Sciences (SPSS) Version 23.0 (SPSS Inc). Categorical variables were described using frequency count and percentages. Continuous variables were represented as mean ± standard deviation (SD). The comparison of blood group with in-hospital adverse outcomes and long-term persistent symptoms was computed using the χ 2 test. Logistic regression analysis was used to compute the odds ratio (OR) and confidence interval (CI) between the ABO blood group and in-hospital adverse outcomes after adjusting for sex. A two-sided p < 0.05 was considered statistically significant. Table 1 (Table 3) .

With regard to the association between the ABO blood group and long-term symptoms following the acute COVID-19 phase, we were able to collect and analyze the data on long-term persistent symptoms from 86 patients after excluding 36 patients who died at the hospital and 47 patients who did not attend follow up visit. Only those long-term symptoms with a prevalence ≥5 were mentioned and included in the statistical analysis. Blood group AB showed higher prevalence of palpitation (p < 0.001) and dizziness (p = 0.02) than other blood groups. There was no significant difference in the distribution of ABO blood groups among other long-term persistent symptoms (Table 4 ).

In the literature, different studies have shown contradictory results regarding the association of blood groups and adverse outcomes related to COVID-19. Also, the potential influence of blood groups on long-term persistent symptoms following acute COVID-19

infection is largely unknown. In the current study, the main aim was to assess the association of the blood groups with COVID-19related in-hospital adverse outcomes and long-term persistent symptoms. We observed a significant association between blood group B and AB with in-hospital death and respiratory support (CPAP or mechanical ventilation) use, respectively, while blood T A B L E 1 Patients' characteristics.

Mean ± SD or n (%) Regarding the association of blood groups B and AB with in-hospital adverse outcomes, emerging data from several studies in different regions reported a higher risk for COVID-19 infection with blood groups B and AB compared to other blood groups. 7, 11, 13, 16, 20 In line with our findings, an Indian epidemiological study conducted by Padhi validation; writing-original draft; and writing-review and editing. All authors have read and approved the final version of the manuscript. The corresponding author had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

The authors declare no conflicts of interest.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Hussein Nafakhi, the corresponding author, affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained ORCID Hussein Nafakhi http://orcid.org/0000-0002-0238-0460

Systematic review and meta-analysis of the susceptibility of ABO blood group to COVID-19 infection

The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A

ABO blood groups and the incidence of complications in COVID-19 patients: a population-based prospective cohort study

Long-term persistent symptoms of COVID-19 infection in patients with diabetes mellitus

Evaluation of masks' internal and external surfaces used by health care workers and patients in coronavirus-2 (SARS-CoV-2) wards

Investigating the relationship between occupation and SARS-CoV2

Blood type and outcomes in patients with COVID-19

ABO blood group association and COVID-19. COVID-19 susceptibility and severity: a review

Potential association of COVID-19 and ABO blood group: an Indian study

The relationship between epidemic influenza (A(H1N1) and ABO blood group

The novel coronavirus SARS-CoV-2 vulnerability association with ABO/Rh blood types

The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19

The impact of ABO blood group on COVID-19 infection risk and mortality: a systematic review and meta-analysis

Association of ABO blood groups with presentation and outcomes of confirmed SARS CoV-2 infection: a prospective study in the largest COVID-19 dedicated hospital in Bangladesh

ABO blood groups and severe outcomes in COVID-19: a meta-analysis

The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes

The association of ABO blood type with the risk and severity of COVID-19 infection

ABO blood groups, COVID-19 infection and mortality

ABO blood group is involved in the quality of the specific immune response anti-SARS-CoV-2

The impact of ABO blood groups on clinical outcomes and susceptibility to COVID-19: a retrospective study in an unselected population

ABO blood group system is associated with COVID-19 mortality: an epidemiological investigation in the Indian population

Associations between blood type and COVID-19 infection, intubation, and death

Why blood group A individuals are at risk whereas blood group O individuals are protected from SARS-CoV-2 (COVID-19) infection: a hypothesis regarding how the virus invades the human body via ABO(H) blood group-determining carbohydrates

Blood group type A secretors are associated with a higher risk of COVID-19 cardiovascular disease complications

Association of ABO blood group with in-hospital adverse outcome and long term persistent symptoms of COVID-19 infection: a single-center longitudinal observational study